Bispecific Antibody Market: Current Analysis and Forecast (2023-2030)

Report Description

Bispecific Antibody Market Size and Forecast (2023-2030)

The bispecific antibody market was valued at USD 7.8 Billion approximately in 2022 and is expected to grow at a CAGR of around 11.2% during the forecast period (2023-2030).

Bispecific Antibody Market Analysis

Bispecific antibodies are engineered molecules to deliver payloads, such as cytotoxic drugs or radioactive isotopes, directly to target cells, enhancing their therapeutic potential. Ongoing research and development efforts aim to optimize the design, efficacy, and safety profile of bispecific antibodies for a wide range of clinical applications. Bispecific antibodies mainly gained prominence in the market due to the rising cases of chronic diseases like cancer. For instance, according to the World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In addition to this, investments in healthcare departments as well as government awareness programs regarding chronic disorders have increased significantly in recent years, which are the key factors that are creating opportunities for the market.

Akeso Biopharma Co., Ltd.; Alexion Pharmaceuticals, Inc.; Amgen Inc.; Genmab A/S; Immunocore Ltd.; Janssen Global Services, LLC; Linton Pharm; Merck KGaA; Genentech, Inc.; Pfizer Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Bispecific Antibody Market “Amongst drug type, emicizumab category to witness higher CAGR during the forecast period”

Based on the drug type, the market is segmented into blinatumomab, emicizumab, amivantamab, and others. The emicizumab segment is expected to grow with a high CAGR in the forecast period owing to the rising drug approvals. For instance, in June 2022, Japan- based Chugai Pharmaceutical Co., Ltd. obtained regulatory approval from the Ministry of Health, Labour and Welfare of Japan for the anti-coagulation factor IXa/X humanized bispecific monoclonal antibody/coagulation factor VIII substitute Hemlibra (emicizumab) for an additional indication of routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A. Emicizumab is a monoclonal antibody developed for treating hemophilia A, a genetic bleeding disorder caused by deficient or defective clotting factor VIII (FVIII). Hemophilia A patients lack sufficient FVIII activity, leading to prolonged bleeding episodes and an increased risk of spontaneous bleeding, particularly into joints and muscles. Emicizumab is designed to mimic the function of FVIII by facilitating the interaction between activated factor IX and factor X, thereby promoting the formation of blood clots. Thus, among the drug types, emicizumab is expected to witness a higher CAGR during the forecast period.

“Amongst indication, cancer category held a significant share in the market in 2022”

Based on the indication, the market is categorized into cancer, hemophilia, macular degeneration, and others. The cancer segment dominated the market in the year 2022 owing to the rising clinical trials for treating cancer. For instance, in May 2022, Merus N.V. initiated a study of bispecific antibody MCLA-145 in patients with advanced or metastatic malignancies. In cancer immunotherapy, bispecific antibodies have garnered considerable interest for their ability to harness the immune system to selectively eliminate tumor cells. By engaging immune cells, such as T cells or natural killer cells, bispecific antibodies can overcome immune evasion mechanisms employed by tumors and enhance antitumor immune responses. Thus, cancer held a significant share of the bispecific antibody market in 2022.

“Amongst regions, APAC to witness higher CAGR during the forecast period”

APAC is expected to grow with a high CAGR in the global bispecific antibody market in the forecast period. Several factors such as a surge in the number of product launches, enhanced accessibility, and diversified healthcare costs are driving the market’s growth during the forecast period. For instance, in November 2023, Roche Pharmaceuticals China announced the approval of its innovative lymphoma drug Columvi (CD20/CD3 bispecific antibody, glofitamab) from the China National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two lines of prior systemic therapy. Further, the increase in incidences of chronic conditions like cancer and macular degeneration is also having a positive impact on the market’s growth. There have been major awareness programs regarding these disorders and product launches in the region. Thus, APAC is expected to witness a higher CAGR during the forecast period.

Bispecific Antibody Market Report Coverage

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:

The global bispecific antibody market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

You can also purchase parts of this report. Do you want to check out a section wise
price list?

Get in touch with team

Research Methodology

Research Methodology for the Bispecific Antibody Market Analysis (2023-2030)

Analyzing the historical market, estimating the current market, and forecasting the future market of the global bispecific antibody market were the three major steps undertaken to create and analyze the adoption of bispecific antibody in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were considered. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global bispecific antibody market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:

Analysis of Historical Market Size

Step 1: In-Depth Study of Secondary Sources:

Detail secondary study was conducted to obtain the historical market size of the bispecific antibody market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.

Step 2: Market Segmentation:

After obtaining the historical market size of the bispecific antibody market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as drug type, indication, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.

Step 3: Factor Analysis:

After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the bispecific antibody market. Further, we conducted factor analysis using dependent and independent variables such as drug type, indication, and regions of bispecific antibody. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the bispecific antibody market sector across the globe.

Current Market Size Estimate & Forecast

Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global bispecific antibody market, and market shares of the segments. All the required percentage shares split and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.

Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2030 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:

• The industry’s market size, in terms of revenue (USD) and the adoption rate of the bispecific antibody market across the major markets domestically
• All percentage shares, splits, and breakdowns of market segments and sub-segments
• Key players in the global bispecific antibody market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market

Market Size and Share Validation

Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.

Split of Primary Participants in Different Regions

Market Engineering

The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global bispecific antibody market. Data was split into several segments & sub-segments after studying various parameters and trends in the areas of drug type, indication, and regions in the global bispecific antibody market.

The main objective of the Global Proteasome Inhibitor Market Study

The current & future market trends of the global bispecific antibody market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:

• Analyze the current and forecast market size of the bispecific antibody market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments.
• Segments in the study include areas of drug type, indication, and regions.
• Define and analyze the regulatory framework for the bispecific antibody industry.
• Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
• Analyze the current and forecast market size of the bispecific antibody market for the major region.
• Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World.
• Company profiles of the bispecific antibody market and the growth strategies adopted by the market players to sustain in the fast-growing market.
• Deep dive regional level analysis of the industry.

You can also purchase parts of this report. Do you want to check out a section wise
price list?

Get in touch with team